Cross-Sector entity
ORIGIN 3 is most often covered alongside Marshall Fordyce, which appears in 2 of these 2 stories. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 2 original sources on average.
2 verified stories tracked
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ORIGIN 3 is most often covered alongside Marshall Fordyce, which appears in 2 of these 2 stories. Coverage clusters in fda-approval, which accounts for 1 of those 2, with the remainder spread across 1 other category. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention ORIGIN 3, all published on July 12, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ORIGIN 3. Shared-story counts are live from our verified record — not editorial picks.
The FDA’s accelerated approval of TRUTAKNA marks the first BAFF/APRIL inhibitor for IgA nephropathy, showing a 42% UPCR reduction over placebo. Healthcare providers now have a therapy targeting upstream disease drivers, with launch imminent and a confirmatory trial ongoing.
Vera Therapeutics scores an accelerated approval for TRUTAKNA in IgA nephropathy, touting a 42% UPCR reduction vs placebo in Phase 3 ORIGIN 3. The dual BAFF/APRIL inhibitor enters a competitive market with a surrogate endpoint—investors await the confirmatory eGFR data.
Source: dailypolitical.com · tickerreport.com
